A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16-24 months

• প্রধান লেখক: Hitt Sharma (লেখক), Sanjay Lalwani (লেখক), Sameer Parekh (লেখক), Pramod Pujari (লেখক), Sunil Shewale (লেখক), Sonali Palkar (লেখক), Neeta Hanumante (লেখক), Shilpa Gokhale (লেখক), Jaganathan Ks (লেখক), Rakesh Kumar (লেখক), Inderjit Sharma (লেখক), Sunil Gairola (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

This first in human study was designed as an open label clinical trial to assess the safety and immunogenicity of SIIPL DTwP-HepB-IPV-Hib (Hexavalent) combination vaccine in healthy toddlers, aged 16-24 months. A total of 24 healthy toddlers were administered a 0.5 ml single dose of SIIPL DTwP-HepB-...